Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tavapadon - Cerevel Therapeutics

Next Previous
Drug Profile

Tavapadon - Cerevel Therapeutics

Alternative Names: PF-06649751; PF-6649751

Latest Information Update: 30 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Cerevel Therapeutics; Pfizer
  • Class Antidementias; Antiparkinsonians; Small molecules
  • Mechanism of Action Dopamine D1 receptor agonists; Dopamine D5 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 25 Sep 2019 Efficacy and safety data from a phase II trial in Parkinson's disease released by Cerevel Therapeutics
  • 23 Sep 2019 Cerevel Therapeutics plans a phase III trial for Parkinson's disease (Early-stage disease, Late-stage disease)
  • 19 Sep 2019 Phase-II clinical trials in Parkinson's disease in USA (PO) before September 2019 (Cerevel Therapeutic's pipeline - September 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top